CA
ORMP icon

Calton & Associates’s Oramed Pharmaceuticals ORMP Stock Holding History

Calton & Associates’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-450
Closed -$3K – 983
2017
Q4 		$3K Buy
+450
New +$4.3K ﹤0.01% 1343

Other funds holding ORMP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
RPC
Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Calton & Associates's ORMP Position: Q1 2018 in Review

Calton & Associates sold out of Oramed Pharmaceuticals (ORMP) in Q1 2018, closing a stake of 450 shares — an estimated $3K sold.

Calton & Associates first reported a position in ORMP in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 21 funds tracked by Wall St. Rank hold ORMP as of Q1 2018.

  • Calton & Associates reported no remaining Oramed Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 450 Oramed Pharmaceuticals shares in Q1 2018, an estimated $3K.
  • Calton & Associates first reported a position in Oramed Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Oramed Pharmaceuticals position peaked at $3K in Q4 2017.
  • 21 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.